NMN's Impact on Inflammation Markers: A Research Review

Nicotinamide mononucleotide (NMN) has garnered substantial interest as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme vital for cellular metabolism and a multitude of biological processes. While much attention centres on its role in mitochondrial function and overall longevity, a growing body of evidence suggests NMN may significantly influence systemic inflammation. This paper critically evaluates the available data on NMN's effects on various inflammation markers.

What the evidence says

Research indicates NMN may attenuate chronic low-grade inflammation, a hallmark of ageing and many chronic diseases. Markers such as high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α) are commonly elevated in states of chronic inflammation. Studies investigating NMN's impact on these markers have shown promising, albeit varied, results across different populations and study designs. While the mainstream view often equates NMN with pure NAD+ boosting, the data concerning its anti-inflammatory effects is often messier, suggesting a nuanced interaction with immune pathways rather than a simple 'on/off' switch.

Mechanism

The anti-inflammatory actions of NMN are primarily mediated through its conversion to NAD+. Increased intracellular NAD+ levels activate sirtuins (SIRT1 and SIRT3), particularly SIRT1, which is a key regulator of inflammation. SIRT1 deacetylates various proteins, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a central mediator of inflammatory responses. By deactivating NF-κB, SIRT1 suppresses the transcription of pro-inflammatory cytokines like IL-6 and TNF-α. This mechanism also involves modulation of cellular energy status and redox balance, indirectly influencing inflammatory pathways. NAD+ also plays a role in DNA repair via PARP enzymes, which, when overactivated by DNA damage, can deplete NAD+ and contribute to inflammation. NMN supplementation, by boosting NAD+, may thus help maintain PARP function without excessive NAD+ consumption, further dampening inflammatory signals. For a deeper understanding of NAD+ precursors and their impact on cellular energy, refer to our work on Mitochondrial Optimization.

Trial data

Several human trials have explored NMN's impact on inflammatory markers. A randomised, double-blind, placebo-controlled trial published in *GeroScience* involving 80 middle-aged and older adults demonstrated that 300 mg/day of NMN for 8 weeks significantly reduced hs-CRP levels by approximately 20% compared to placebo. Another study, focusing on overweight or obese postmenopausal women, administered 300 mg/day of NMN for 10 weeks and observed a reduction in IL-6 and TNF-α, alongside improvements in metabolic parameters. While these trials offer encouraging signs, their relatively short durations and specific cohorts mean broader generalisation requires caution. Some smaller studies, particularly those involving younger, healthy individuals, have shown less dramatic changes in inflammatory markers, suggesting the effect may be more pronounced in populations with pre-existing low-grade inflammation. Our editorial take is that while early trials are promising, robust, large-scale, long-term RCTs are still needed to solidify these findings and explore the full spectrum of NMN's anti-inflammatory potential.

For those looking to track changes in their own inflammatory status, our Biomarker insights tool offers a comprehensive approach to monitoring markers like hs-CRP and other key health indicators.

Effect sizes and biomarkers

The observed effect sizes on inflammation markers with NMN supplementation vary. In the aforementioned *GeroScience* study, a 20% reduction in hs-CRP is clinically meaningful for individuals with elevated baseline levels, potentially indicating a lower risk of cardiovascular events. Reductions in IL-6 and TNF-α, even if modest (typically in the range of 10-15% in observed trials), can contribute to a decrease in systemic inflammatory load. Other biomarkers of interest include fasting insulin and ApoB, which are often correlated with chronic inflammation. While direct evidence for NMN's impact on these specific markers related to inflammation is emerging, the overall metabolic improvements seen with NAD+ precursors suggest a potential indirect benefit. Tracking these changes requires consistent monitoring, as outlined in our Executive Performance protocol. Consider linking your NMN regimen to a broader Healthspan Foundation approach for synergistic benefits.

Safety and contraindications

NMN has generally been well-tolerated in human clinical trials, with no serious adverse events reported at doses up to 1000 mg/day for several months. Common side effects, when reported, have been mild and infrequent, including minor gastrointestinal upset. However, long-term safety data, particularly for durations exceeding one year, remains limited. Individuals with pre-existing medical conditions, especially those undergoing active treatment for inflammatory or autoimmune disorders, should consult their healthcare provider before initiating NMN supplementation. The MHRA in the UK classifies NMN as a novel food, meaning its availability as a supplement is regulated, and consumers should source from reputable suppliers. Always remember to check with a healthcare professional before adding new supplements to your routine; more information on this can be found at /legal/disclaimer.

Practical implications

Given the role of chronic low-grade inflammation in ageing and disease, NMN's potential to modulate inflammatory markers holds significant practical implications. For individuals experiencing elevated hs-CRP, IL-6, or TNF-α, NMN supplementation could be a complementary strategy alongside lifestyle interventions. While NMN is available from various retailers, including Boots and independent health food shops, the quality and purity can vary, so it is advisable to choose products from brands that provide third-party testing. Typical daily dosages in studies range from 250 mg to 500 mg, sometimes escalating to 1000 mg/day. It is advisable to start with a lower dose, such as 250 mg, and monitor effects. For broader information on NAD+ supplementation, including NMN, visit our research library. Tracking your progress using a tool like our Biomarker insights tool can provide objective data on your body's response.

Bottom line

Based on current evidence, NMN appears to have a measurable, albeit modest, impact on systemic inflammation markers like hs-CRP, IL-6, and TNF-α, primarily through NAD+-dependent mechanisms involving sirtuins and NF-κB. For individuals seeking to address chronic low-grade inflammation, particularly those with age-related inflammatory burdens, NMN could be a worthwhile addition to a comprehensive health strategy. However, it should not be viewed as a standalone solution, but rather as part of a holistic approach that includes diet, exercise, and other health interventions. Skip if you have no measurable inflammation or are seeking dramatic, instant anti-inflammatory effects typically associated with pharmaceutical interventions. It's worth it for those looking for a long-term, subtle modulation of inflammatory pathways to support healthy ageing.